Navigation Links
Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
Date:9/19/2008

targeting used by the PSD allows for an extended observation period, dependent only upon the environmental support available for the cells. Further, non-invasive electrical stimulation can be done without causing damage to the cells while optical targeting enables highly controlled depolarization of only target cells. The PSD can also be used in place of pharmacological agonist stimulation, which does not allow for specific cell targeting and/or rapid repetitive depolarization, where such experimental capabilities would be desirable.

The PSD system controller is a fully contained, easy to use electronics base that readily fits into any bench-top environment. Cells for experimentation are grown on the silicon PSD substrates that fit in industry standard 24 well plates for cell culture and storage, and are then mounted onto the reusable PSD experimental chamber for live cell observation using any standard up-right microscope. Current promotion bundles including the PSD controller, experimental chambers, and cell culture substrates begin at $3,550.00.

Advancing the frontiers of excitable cell research, such as in neurons and muscle cells will serve to further our understanding of the mechanisms underlying cellular structure/function relationships. Additionally, it will enable scientists to better elucidate how these mechanisms go awry during disease states and potentially how to better address (and/or prevent) the disease state (and/or injury) following onset. Further, the diagnostic testing and drug discovery potential of the PSD will provide insights into the identification and development of new therapeutics.

About Neurosilicon

Neurosilicon develops novel brain-computing interfaces to expand the scientific understanding of the human brain and to revolutionize and improve the effectiveness of drug discovery. The company's flagship product, the Photoconductive Stimulation Device (PSD) stimulates excitable cells in a precise and controllabl
'/>"/>

SOURCE Neurosilicon
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
2. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
3. Novel Compound Shows Promise for Treatment of Alcoholism
4. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
5. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
6. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
7. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
10. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 XBiotech announced ... study in patients with moderate to severe plaque ... open-label Phase II trial evaluated the potential benefit ... that targets interleukin-1 alpha (IL-1a). IL-1a is a ... present in skin lesions. The Company claims that ...
(Date:3/4/2015)... , March 4, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization of ... it will present at the Barclays Global Healthcare ... the Loews Miami Beach Hotel in Miami ... Peter , M.D., President and Chief Executive Officer of ...
(Date:3/4/2015)... -- Following the reintroduction of the Comprehensive Addiction ... a report today urging policymakers to take steps ... through more effective use of medication-assisted treatment (MAT).  ... Expanding Access to Medication-Assisted Treatment to Address the ... and economic advantages of medication-assisted treatment along with ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2
... According to an overview of industry data released ... , in Fiscal Year 2011, pharmaceutical companies continued a ... delay the introduction of lower-cost prescription drug alternatives for ... that drug companies entered into 28 potential pay-for-delay ...
... ABAXIS, Inc. (NasdaqGS: ABAX), a medical products company manufacturing ... the second fiscal quarter ended September 30, 2011. ... $40.0 million, up 13% over last year,s comparable quarter. ... over last year,s comparable quarter. Veterinary market sales ...
Cached Medicine Technology:FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 2FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 2Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 4Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 5Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 6Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 7Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 8Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 9
(Date:3/4/2015)... Imagine No Malaria’s 2014 World Malaria Day campaign has ... an honor given to nonprofit causes that make a difference. ... Conference (NTC15) in Austin, Texas. The Rev. Bobbi Kaye ... was on hand for the presentation; she is a member ... No Malaria was one of five finalists selected by Care2, ...
(Date:3/4/2015)... 04, 2015 Dr. Christopher Asandra, M.D., ... Center today lamented the FDA’s recent decision to ... (TRT). He argued that FDA’s conclusions are not supported ... who suffer from testosterone deficiency. , “The FDA appears ... testosterone replacement therapy,” said Dr. Asandra. “There is not ...
(Date:3/4/2015)... Austria (PRWEB) March 04, 2015 ... reduce subjectivity in density assessment and help improve ... of numerous abstracts accepted for presentation at the ... 2015. Ten abstracts - eight posters and ... Volpara Solutions’ automated breast density and quantitative breast ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Starting February ... LASIK and PRK procedures at their new location in ... Dr. Joseph King and Dr. Gabriel Chu also provide ... in Surrey is named Fraser Valley Cataract and Laser ... accredited by the College of Physicians and Surgeons of ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 State officials ... of the School of Public Health at Georgia State ... funds were awarded by Georgia’s Division of Family and ... support the DFCS Call Center. , The 1-800-CHILDREN ... by providing information and referral services that promote the ...
Breaking Medicine News(10 mins):Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:King LASIK relocates to Surrey, British Columbia 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... CHICAGO For years, it was believed that obese women ... body fat actually protected against bone loss. However, a study ... of North America (RSNA) found that having too much internal ... bone health. "We know that obesity is a major ...
... , CAMBRIDGE, Mass. (November 29, 2010) Whitehead Institute ... the microRNA 125b (miR-125b) can independently cause leukemia and ... this week,s online edition of the Proceedings of the ... in many cancers, but in humans and mice, can ...
... With the emergence of an epidemic of obesity and type ... habits that may affect the risk of metabolic diseases is ... drinkers tend to have about 30% lower risk of developing ... tend to be at lower risk of developing metabolic ...
... Goodwin HealthDay Reporter , MONDAY, Nov. 29 (HealthDay ... teens over the last few decades, with some of the ... a new report. In one startling statistic cited in ... and Quality found that hospitalizations for eating disorders jumped by ...
... iridescence of a butterfly,s wing, investigators at the University ... and Applied Sciences have developed a color-changing patch that ... indicate the strength of exposure to blasts from explosives ... color change to the intensity of exposure to provide ...
... , MONDAY, Nov. 29 (HealthDay News) -- Children and teens ... triclosan may be at increased risk for hay fever and ... can actually make people sick, researchers say. The study ... bisphenol A (BPA) may weaken an adult,s immune system. ...
Cached Medicine News:Health News:Belly fat puts women at risk for osteoporosis 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:Moderate alcohol consumption lowers the risk of metabolic diseases 2Health News:Rate of Eating Disorders in Kids Keeps Rising 2Health News:Rate of Eating Disorders in Kids Keeps Rising 3Health News:Color-changing 'blast badge' detects exposure to explosive shock waves 2Health News:Too Much Hygiene May Affect Immune System, Study Suggests 2
This optimal design addresses low-cost, simple, non-invasive ankle distraction....
A straightforward, versatile approach to arthroscopically assisted pin placement in either the ankle or wrist....
... The BTA stat Test ... for the qualitative detection of ... persons diagnosed with bladder cancer. ... as an aid in the management ...
ThyroTest by ThyroTec, Inc. is a rapid immunoassay, similar to a rapid pregnancy test. By using 2 drops of blood from a finger stick and 5 drops of diluent, a qualitative TSH level is inicated in min...
Medicine Products: